Form 4: Akoya Biosciences Director Acquires Stock Options
SEC Form 4
Director Scott Mendel acquired 44,959 stock options in Akoya Biosciences on October 2, 2024, according to a Form 4 filing.
Summary
- On October 2, 2024, Scott Mendel, a director of Akoya Biosciences, Inc. (AKYA), acquired 44,959 stock options.
- The exercise price of these options is $2.68.
- The options vest ratably on a quarterly basis over four quarters, starting January 1, 2025, subject to continuous service.
- The options expire on October 2, 2034.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock option grants.
Industry Context
This is a routine disclosure of stock option grants to a company director, which is a common practice in publicly traded companies to incentivize and retain key personnel.
Stakeholder Impact
- The grant of stock options could potentially dilute existing shareholders' equity if the options are exercised in the future.
Key Dates
| Date | Description |
|---|---|
| 10/02/2024 | Date of the stock option grant. |
| 01/01/2025 | First vesting date for the options. |
| 10/02/2034 | Expiration date of the options. |
| 10/04/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.